Cyclobenzaprine very low dose - Tonix Pharmaceuticals

Drug Profile

Cyclobenzaprine very low dose - Tonix Pharmaceuticals

Alternative Names: KRL-102; TNX-102; TNX-102 SL; Tonmya; VLD-cyclobenzaprine

Latest Information Update: 15 Mar 2017

Price : $50

At a glance

  • Originator Vela Pharmaceuticals
  • Developer Tonix Pharmaceuticals Holding Corp
  • Class Dibenzocycloheptenes; Muscle relaxants; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Histamine H1 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Post-traumatic stress disorders
  • Discontinued Fibromyalgia

Most Recent Events

  • 01 Mar 2017 Phase-III clinical trials in Post-traumatic stress disorder in USA (Sublingual) (NCT03062540)
  • 19 Dec 2016 Cyclobenzaprine very low dose - Tonix Pharmaceuticals receives Breakthrough Therapy status for Post-traumatic stress disorder in USA
  • 08 Dec 2016 Efficacy data from the phase II AtEase trial in Post-traumatic stress disorder released by Tonix Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top